Loading data for BEIGF — first visit, this takes a few seconds.
BeOne Medicines AG (BEIGF)
OTC Markets OTCPK: BEIGF
· Real-Time Price · USD
21.95
+0.00 (0.00%)
At close: Sep 11, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
BeOne Medicines AG (BEIGF) Stock Price, Analysis & Data
No data available
| Bid | 25.14 |
| Market Cap | 32.3B |
| Revenue (ttm) | 6.13B |
| Net Income (ttm) | 656M |
| 0.52 | |
| 0.43 | |
| 51.04 | |
| n/a | |
| P/B (ttm) | 6.23 |
| P/S (ttm) | 5.27 |
| Earnings Date | Nov 5, 2026 |
| Ask | 29.68 |
| Volume | 100 |
| Avg. Volume (20D) | 31 |
| Open | 23.75 |
| Previous Close | 21.95 |
| Day's Range | 23.75 - 23.75 |
| 52-Week Range | 15.95 - 25.29 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BEIGF
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVA...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 18, 2023
Employees 12,000
Stock Exchange OTC Markets OTCPK
Ticker Symbol BEIGF
Website https://beonemedicines.com
Financial Performance
In 2025, BeOne Medicines's revenue was 5.34B, an increase of 40.23% compared to the previous year's 3.81B. Earnings were 286.93M, a decrease of -144.5%.
Financial StatementsEarnings Surprise
BeOne Medicines has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
BeOne Medicines AG is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2